|
Report Date : |
26.07.2013 |
IDENTIFICATION DETAILS
|
Name : |
TATA MEMORIAL CENTRE (ACTREC) |
|
|
|
|
Registered
Office : |
Dr. E Borges Road, Parel, Mumbai – 400012, Maharashtra |
|
|
|
|
Country : |
India |
|
|
|
|
Year of
Establishment: |
1941 |
|
|
|
|
Legal Form : |
Research Centre |
|
|
|
|
Line of Business
: |
Cancer Research Centre. |
|
|
|
|
No. of Employees
: |
Information declined by the management |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (51) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established medical centre commissioned by Sir Dorabji Tata
Trust on 28 February 1941. Later in 1957 the hospital was taken over by the
ministry of health (Government of India) Our executives were unable to contact the subject. So no detail could be made available. However, ratings take into consideration the strong support provided
by the Government of India. The subject can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION DECLINED
Management Non – Cooperative (91-22-24177000)
LOCATIONS
|
Registered Office : |
Dr. E Borges Road, Parel, Mumbai – 400012, Maharashtra, India |
|
Tel. No.: |
91-22-24177000 |
|
Fax No.: |
91-22-24146937 |
|
E-Mail : |
|
|
Website : |
MANAGEMENT
|
Name : |
Dr. R.A. Badwe |
|
Designation : |
Director |
|
|
|
|
Name : |
Dr R Sarin |
|
Designation : |
Director |
|
|
|
|
Member: |
Dr. K.B.Sainis, PhD |
|
Designation: |
Chairperson |
|
Affiliation: |
Director, Biomedical Group, BARC, Trombay, Mumbai-85. |
|
Role: |
Basic Scientist |
|
|
|
|
Member: |
Dr. Tapan Saikia, MD |
|
Designation: |
Co-Chairperson |
|
Affiliation: |
Medical Oncologist, Prince Aly Khan Hospital |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. Vikram Gota, MD |
|
Designation: |
Member secretary |
|
Affiliation: |
Clinical Pharmacology, ACTREC |
|
Role: |
Clinical Pharmacologist |
|
|
|
|
Member: |
Dr. Rita Mulherkar, PhD |
|
Designation: |
Member |
|
Affiliation: |
Scientist, ACTREC |
|
Role: |
Basic Scientist |
|
|
|
|
Member: |
Dr. Sorab Dalal, PhD |
|
Designation: |
Member |
|
Affiliation: |
Scientist, ACTREC |
|
Role: |
Basic Scientist |
|
|
|
|
Member: |
Dr. Abhijit De, PhD |
|
Designation: |
Member |
|
Affiliation: |
Scientist, ACTREC |
|
Role: |
Basic Scientist |
|
|
|
|
Member: |
Dr. Nobhojit Roy, MS |
|
Designation: |
Member |
|
Affiliation: |
Surgeon, BARC Hospital |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. Reena Nair, MD |
|
Designation: |
Member |
|
Affiliation: |
Medical Oncologist, Tata Memorial Hospital |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. Kumar Prabhash, MD, DM |
|
Designation: |
Member |
|
Affiliation: |
Medical Oncologist, Tata Memorial Hospital |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. Asawari Patil, MD |
|
Designation: |
Member |
|
Affiliation: |
Pathologist, Tata Memorial Centre |
|
Role: |
Clinician / Medical Scientist |
|
|
|
|
Member: |
Dr. Vedang Murthy, MD |
|
Designation: |
Member |
|
Affiliation: |
Radiation Oncologist, ACTREC |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. Amit Sengupta, MD, PhD |
|
Designation: |
Member |
|
Affiliation: |
Biomedical Engineer, ACTREC Gynecologist,
CGHS |
|
Role: |
Clinician / Medical Scientist |
|
|
|
|
Member: |
Dr. Mahesh Mohite, MD |
|
Designation: |
Member |
|
Affiliation: |
Pediatrician, Mohite Hospital, Panvel |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. Tejpal Gupta, MD |
|
Designation: |
Member |
|
Affiliation: |
Radiation Oncologist, ACTREC |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. Aliasgar Moiyadi, MS, MCh |
|
Designation: |
Member |
|
Affiliation: |
Surgical Oncologist, ACTREC |
|
Role: |
Clinician |
|
|
|
|
Member: |
Dr. B.B. Singh, LLB, PhD |
|
Designation: |
Member |
|
Affiliation: |
Advocate, Mumbai High Court |
|
Role: |
Legal Expert |
|
|
|
|
Member: |
Dr. Bakhtaver Mahajan, PhD |
|
Designation: |
Member |
|
Affiliation: |
Indian Women Scientists Association (IWSA) |
|
Role: |
Social Scientist |
|
|
|
|
Member: |
Mrs. Sadhana Kannan, M.Sc |
|
Designation: |
Member |
|
Affiliation: |
Statistician, ACTREC |
|
Role: |
Medical Scientist |
|
|
|
|
Member: |
Mr. T.B.Sheshshai |
|
Designation: |
Member |
|
Affiliation: |
Retired BARC Employee |
|
Role: |
Theologian |
|
|
|
|
Member: |
Mrs. Karuna Jaggi, MA |
|
Designation: |
Member |
|
Affiliation: |
Freelance Counselor |
|
Role: |
Lay person |
|
|
|
|
Member: |
Dr. R. Munagekar |
|
Designation: |
Member |
|
Affiliation: |
Pathologist and Medicolegal Consultant,
Sadhana Pathology Laboratory |
|
Role: |
Legal Expert |
|
|
|
|
Member: |
Mrs. Tyeba Bilgrami |
|
Designation: |
Member |
|
Affiliation: |
St. Jude Childcare Centre |
|
Role: |
Lay person |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
No |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact
person |
No |
|
11] |
Turnover of firm for last
three years |
No |
|
12] |
Profitability for last
three years |
No |
|
13] |
Reasons for variation
<> 20% |
-- |
|
14] |
Estimation for coming
financial year |
No |
|
15] |
Capital in the business |
No |
|
16] |
Details of sister
concerns |
No |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details
(if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm
/ promoter involved in |
-- |
|
23] |
Banking Details |
No |
|
24] |
Banking facility details |
No |
|
25] |
Conduct of the banking
account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
No |
|
28] |
Incorporation details, if
applicable |
No |
|
29] |
Last accounts filed at
ROC |
No |
|
30] |
Major Shareholders, if
available |
No |
|
31] |
Date of Birth of
Proprietor/Partner/Director, if available |
No |
|
32] |
PAN of Proprietor/Partner/Director,
if available |
No |
|
33] |
Voter ID No of
Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating,
if available |
No |
AS PER WEBSITE
DETAILS
HISTORY
The origins of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) are rooted in the Indian Cancer Research Centre (ICRC), which was established in 1952 in Parel, Mumbai, under the purview of the Ministry of Health, Government of India. In 1966, ICRC was renamed the Cancer Research Institute (CRI) and amalgamated with the Tata Memorial Hospital (TMH), creating the first comprehensive cancer centre in India - the Tata Memorial Centre (TMC), an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India.
Over the years, as the institute grew in repute and staff strength, with several new disciplines introduced into its repertoire, an acute shortage of space led to the search for a larger campus. The ACTREC project was conceptualized by the DAE in November 1983. During the period 1985-1987, DAE acquired a huge 60 acre plot of land from CIDCO in Navi Mumbai, the newly developing city across the harbour, and it was decided to set up a much larger institute on this campus.
The foundation stone for this campus - the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), located near the foothills of the Sahyadri mountain ranges in Kharghar, Navi Mumbai, was formally laid in May 1997 by Dr. R. Chidambaram, Chairman, AEC and Secretary, DAE. In August 2002, in its 50th year, CRI moved in toto from Mumbai to Navi Mumbai to become the basic research wing of ACTREC, and started functioning from its new premises at Kharghar. In December 2002, CRI celebrated its Golden Jubilee, with the pledge to 'not remain content' with its stature and recognition worldwide as the premier Indian institute conducting research on cancer, but to scale new heights at its ACTREC campus.
Today, ACTREC serves as a new state-of-the-art R and D satellite of TMC and has the specific mandate to function as a national centre for treatment, research and education in cancer. ACTREC, which at present comprises of the basic and clinical research wings and a 50-bed hospital, will carry out mission-oriented research and development on cancers prevalent in the Indian sub-continent, and where there are internationally competitive opportunities, will use state-of-the-art technology in partnership with TMH.
NEWS
C-DAC,
TATA MEMORIAL CENTRE COLLABORATE FOR CANCER RESEARCH
FEBRUARY 15, 2012
The Centre for Development of Advanced Computing (C-DAC) is
collaborating with Tata Memorial Centre for undertaking high-end research in
the field of cancer through its supercomputing facility.
“Finding answer to cancer cure is a challenge before us. We
have tied up with Tata memorial Centre for high-end cancer research. While they
will do the clinical research, we will provide the supercomputing facility to
undertake greater volume of research,” Associate Director and Head of the
Department (HOD)-Bioinformatics C-DAC, Pune, Rajendra Joshi told reporters here
on Tuesday.
C-DAC has also come up with a new dedicated super computing
cluster - Biochrome, which would help undertake more complicated research work
in the field of life sciences at much higher speed and lesser energy
consumption.
The Bioinformatics Resources and Applications Facility
(BRAF) at C-DAC is an effort towards providing high-end supercomputing facility
to the researchers working in the areas of life sciences. BRAF is funded by the
central government.
Biochrome will be formally launched on Wednesday at a
symposium on 'Accelerating Biology 2012: Computing to Decipher'.
“The availability of hundreds of genomes in a short time is expected to
revolutionise area of medical diagnostics and health care,” Joshi said.
This tsunami of data has led to a sea change in the storage
and computing requirements. In order to gear up to tackle these challenges most
biologists are adopting the use of cyber infrastructure, he added.
The cluster has a peak computing capacity of 5 TeraFlop with
504 computing cores using 6 core Intel Xeon 2.67 GHz processor.
Apart from Tata Memorial Centre, Centre for Development of
Advanced Computing is also collaborating with organisations like National
Cancer Institute (NCI) of National Institutes of Health (NIH) (USA), Roslin
Institute (UK), University of Edinburgh (UK), National Centre for Cell Science
(Pune), University of Pune and National Chemical Laboratory (Pune) for advanced
research in life sciences.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or investigation
registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No available
information exist that suggest that subject or any of its principals have been
formally charged or convicted by a competent governmental authority for any
financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.59.45 |
|
|
1 |
Rs.91.24 |
|
Euro |
1 |
Rs.78.44 |
INFORMATION DETAILS
|
Information
Gathered by : |
SVA |
|
|
|
|
Report Prepared
by : |
KVT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
51 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NB |
NEW BUSINESS |
||
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.